Hathal Haddad: 28 Days Until Brachytherapy Awareness Day 2026
oncodaily - Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared a post on LinkedIn: “28 Days Until Brachytherapy Awareness Day 2026 The Original Adaptive […]
AI Summary: Radiation oncologists and advocates are publicly gearing up for Brachytherapy Awareness Day, using countdowns and outreach to raise awareness of image‑guided and salvage brachytherapy techniques. The push emphasizes education, patient access and the specialty’s role in targeted cancer treatment — all packaged with the predictable mix of pride and promotional zeal.
- Countdown and technique spotlights ahead of Brachytherapy Awareness Day (4)
- Guidelines, re-irradiation debates and professional meeting updates (4)
Countdown and technique spotlights ahead of Brachytherapy Awareness Day
Guidelines, re-irradiation debates and professional meeting updates
Purdue Researchers Develop Next-Generation Automated Platform to Accelerate Drug Discovery – Purdue Institute for Cancer Research
oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]
AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.
More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.
Natalie Krebs, Iowa Public Radio / kffhealthnews - Amid advancements in treatment and screening, more Americans are surviving the disease. But many are left with psychological scars, such as lingering anxiety and depression.
AI Summary: New analyses show cancer survival rates have improved, yet many survivors continue to face persistent mental‑health burdens including anxiety, depression and social isolation. Experts call for integrated psychosocial care, routine screening and long‑term support services to address survivorship needs, arguing that beating cancer shouldn’t mean signing up for a second, emotional marathon.
- MASCC 2026: Global spotlight on supportive cancer care (4)
- Practical survivorship needs: rehab, fertility, cardiac care (5)
- Psychosocial oncology programs, research and education initiatives (4)
- Rising survivorship, rising mental‑health burdens (5)
- All Other Stories
MASCC 2026: Global spotlight on supportive cancer care
Practical survivorship needs: rehab, fertility, cardiac care
Psychosocial oncology programs, research and education initiatives
Rising survivorship, rising mental‑health burdens
All Other Stories
Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment
esmo - Findings from the MajesTEC-9 study
AI Summary: Clinical data show teclistamab significantly improves survival for patients with multiple myeloma after one to three prior therapies. Those results have ignited discussions about moving the bispecific antibody earlier in treatment algorithms and prompted labs and clinicians to reassess sequencing strategies across relapsed and refractory myeloma.
FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.